MAPT and dementia: The PET tracers in AD diagnostic imaging started from the radiolabelled glucose analogue [18F] FDG based on dementia-impaired brain glucose metabolism, then progressed into the target-specific small molecules binding to Aβ and tau species with high selectivity over the two past decades, revealing more and more facts behind the AD neurotoxicity in vivo.